-
Company Insights
Innovation and Patenting activity of Hansae Co., Ltd. Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Hansae Co., Ltd. Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Hansa Biopharma AB Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Hansa Biopharma AB Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
Sweden General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
Sweden General Insurance Market Report Overview The gross written premium of the Sweden general insurance market was SEK102.5 billion ($10.1 million) in 2023 and is expected to achieve a CAGR of more than 4% during 2024-2028. The Sweden general insurance market research report provides in-depth market analysis, including insights into the lines of business in the country’s general insurance industry. Furthermore, the report provides a detailed outlook by product category as well as values for key performance indicators, including gross...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBI-110 in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-110 in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBI-110 in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Hemorrhage – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemorrhage - Drugs In Development, 2023’, provides an overview of the Hemorrhage pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drugs In Development, 2023’, provides an overview of the Granulomatosis with Polyangiitis (Wegener's Granulomatosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Vasculitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Vasculitis - Drugs In Development, 2023’, provides an overview of the Vasculitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Drugs In Development, 2023’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Kidney Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Kidney Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...